Dynavax Technologies Corporation Stock News

The broader stock market bounce and news from China are fueling gains for all four vaccine stocks.

Dynavax and Novavax both reported Q4 2021 earnings after hours on 02/28/2022 with heavy pandemic revenues, but only one had earnings. Both issued positive guidance as the state of the pandemic makes f

ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.

Investors weren't inspired by the bitoech's mixed Q4.

FATE reports a wider loss on increased R&D expenses in the fourth quarter.

Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.

Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.

Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.

Today, we 'circle back' on Dynavax Technologies, a biotech concern that just delivered solid fourth quarter results.

DVAX earnings call for the period ending December 31, 2021.

DVAX earnings call for the period ending December 31, 2021.

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -20.29% and 14.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Dynavax press release (DVAX): Q4 GAAP EPS of $0.55 misses by $0.09.Revenue of $195.07M (+897.8% Y/Y) misses by $13.8M.Shares +3.59%.2022 Financial Guidance: Full year CpG 1018…